Syndax Pharmaceuticals (FRA:1T3) Cyclically Adjusted FCF per Share: €-2.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
20 GF Score
Price €19.09
! 7 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Cyclically Adjusted FCF per Share?

Syndax Pharmaceuticals FRA:1T3 -3.15% 20 Cyclically Adjusted FCF per Share is €-2.16 as of Mar. 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 20/100. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Syndax Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.493. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.16 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Syndax Pharmaceuticals was -12.50% per year. The lowest was -12.50% per year. And the median was -12.50% per year.

As of today (2026-07-24), Syndax Pharmaceuticals's current stock price is €19.09. Syndax Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-2.16. Syndax Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Syndax Pharmaceuticals  (FRA:1T3) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Syndax Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Syndax Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.66 -1.80 -2.00 -1.57

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 -2.12 -2.20 -1.57 -2.16

FRA:1T3 vs IOVA, GLUE, TYRA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:1T3
20GF Score
Syndax Pharmaceuticals Inc FRA:1T3
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syndax Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.493/330.2130*330.2130
=-0.493

Current CPI (Mar. 2026) = 330.2130.

Syndax Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.349 241.018 -0.478
201609 -0.573 241.428 -0.784
201612 -0.542 241.432 -0.741
201703 -0.650 243.801 -0.880
201706 -0.539 244.955 -0.727
201709 -0.384 246.819 -0.514
201712 -0.448 246.524 -0.600
201803 -0.664 249.554 -0.879
201806 -0.525 251.989 -0.688
201809 -0.621 252.439 -0.812
201812 -0.493 251.233 -0.648
201903 -0.551 254.202 -0.716
201906 -0.351 256.143 -0.453
201909 -0.245 256.759 -0.315
201912 -0.362 256.974 -0.465
202003 -0.420 258.115 -0.537
202006 -0.468 257.797 -0.599
202009 -0.352 260.280 -0.447
202012 -0.279 260.474 -0.354
202103 -0.368 264.877 -0.459
202106 -0.387 271.696 -0.470
202109 -0.408 274.310 -0.491
202112 1.500 278.802 1.777
202203 -0.646 287.504 -0.742
202206 -0.634 296.311 -0.707
202209 -0.475 296.808 -0.528
202212 -0.342 296.797 -0.381
202303 -0.528 301.836 -0.578
202306 -0.469 305.109 -0.508
202309 -0.599 307.789 -0.643
202312 -0.523 306.746 -0.563
202403 -0.902 312.332 -0.954
202406 -0.781 314.175 -0.821
202409 -0.657 315.301 -0.688
202412 -0.633 315.605 -0.662
202503 -1.022 319.799 -1.055
202506 -0.882 322.561 -0.903
202509 -0.694 324.800 -0.706
202512 -0.683 324.054 -0.696
202603 -0.493 330.213 -0.493

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.16 mean?
Syndax Pharmaceuticals (FRA:1T3) has a Cyclically Adjusted FCF per Share of €-2.16 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Syndax Pharmaceuticals and its competitors.
Is Syndax Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Syndax Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-2.16. Overall, Syndax Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Cyclically Adjusted FCF per Share compare to IOVA and GLUE?
Syndax Pharmaceuticals' Cyclically Adjusted FCF per Share of €-2.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Cyclically Adjusted FCF per Share of €-2.16. The current Cyclically Adjusted FCF per Share is €-2.16. Syndax Pharmaceuticals' overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Cyclically Adjusted FCF per Share is €-2.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
20GF Score

Get the complete analysis for FRA:1T3

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.09
Price